Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1753 (LINC01753) is a lincRNA—a long non-coding RNA transcript located in the intergenic regions of the genome, meaning it does not overlap with protein-coding genes[1][3]. LincRNAs play regulatory roles in the cell, particularly in modulating gene expression at both transcriptional and post-transcriptional levels, and often function as molecular sponges for microRNAs[5]. Aberrant expression of lincRNAs, including those similar to LINC01753, has been implicated in cancer pathogenesis, contributing to deregulation of signaling pathways, promotion of cell proliferation, inhibition of apoptosis, and oncogenic transformation[5]. However, LINC01753 itself is not a receptor, enzyme, transporter, nor is it currently recognized as a direct therapeutic target, and there are no known drugs targeting it specifically[1][3]. It remains a subject of study for its potential as a cancer biomarker or therapeutic target in the future.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1753 (LINC01753).